TELIX Pharmaceuticals Ltd (TLX) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.066x

Based on the latest financial reports, TELIX Pharmaceuticals Ltd (TLX) has a cash flow conversion efficiency ratio of 0.066x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$27.98 Million ≈ $19.80 Million USD) by net assets (AU$421.94 Million ≈ $298.55 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is TELIX Pharmaceuticals Ltd worth for the company's overall valuation and market capitalisation.

TELIX Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)

This chart illustrates how TELIX Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

TELIX Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of TELIX Pharmaceuticals Ltd ranked by their cash flow conversion efficiency. Explore TLX cash to earnings ratio to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
SEB SA PA:SK	0.051x
Guangdong Provincial Expressway Development Co Ltd SHE:000429	0.085x
Acter Co Ltd TWO:5536	0.077x
Willscot Mobile Mini Holdings Corp A NASDAQ:WSC	0.178x
Scotts Miracle-Gro Company NYSE:SMG	-0.768x
Proya Cosmetics Co Ltd Class A SHG:603605	-0.014x
KENON HLDGS LTD F:76N	0.032x
Netwealth Group Ltd AU:NWL	0.436x

Annual Cash Flow Conversion Efficiency for TELIX Pharmaceuticals Ltd (2017–2024)

The table below shows the annual cash flow conversion efficiency of TELIX Pharmaceuticals Ltd from 2017 to 2024. View TLX live share price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	AU$568.21 Million ≈ $402.05 Million	AU$43.03 Million ≈ $30.45 Million	0.076x	-52.79%
2023-12-31	AU$148.91 Million ≈ $105.36 Million	AU$23.88 Million ≈ $16.90 Million	0.160x	+119.29%
2022-12-31	AU$76.92 Million ≈ $54.42 Million	AU$-63.97 Million ≈ $-45.26 Million	-0.832x	+94.89%
2021-12-31	AU$3.64 Million ≈ $2.58 Million	AU$-59.33 Million ≈ $-41.98 Million	-16.290x	-65771.77%
2020-12-31	AU$79.02 Million ≈ $55.91 Million	AU$1.96 Million ≈ $1.39 Million	0.025x	+107.52%
2019-12-31	AU$70.73 Million ≈ $50.05 Million	AU$-23.33 Million ≈ $-16.51 Million	-0.330x	+15.88%
2018-12-31	AU$52.90 Million ≈ $37.43 Million	AU$-20.75 Million ≈ $-14.68 Million	-0.392x	-220.50%
2017-12-31	AU$49.29 Million ≈ $34.88 Million	AU$-6.03 Million ≈ $-4.27 Million	-0.122x	--

About TELIX Pharmaceuticals Ltd

AU:TLX Australia Biotechnology

Market Cap

$4.20 Billion

AU$5.94 Billion AUD

Market Cap Rank

#4665 Global

#114 in Australia

Share Price

AU$17.75

Change (1 day)

+8.63%

52-Week Range

AU$8.63 - AU$17.75

All Time High

AU$31.14